Page 2 - Epidiolex News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Jazz Pharmaceuticals to acquire GW Pharma for $7.2bn 8th February 2021 GW is focused on the discovery and development of therapeutics from its proprietary cannabinoid product platform. The company’s lead product is Epidiolex (cannabidiol) oral solution, which is approved in patients aged one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome and Tuberous Sclerosis Complex (TSC). Epidiolex was the first plant-derived cannabinoid treatment approved by the US Food and Drug Administration, and is also approved as Epidyolex by the European Medicines Agency (EMA). The EMA approved the products fr use in patients aged two-years and older for the adjunctive treatment of seizures associated with LGS and Dravet syndrome, in conjunction with clobazam.

Bruce cozaddEuropean medicines agencyJazz pharmaceuticalsDrug administrationLennox gastaut syndromeDravet syndromeTuberous sclerosis complexJustin goverGw pharmaceuticalsMergers and acquisitionsஜாஸ் மருந்துகள்கிழங்கு ஸ்க்லரோசிஸ் சிக்கலானஜஸ்டின் ஆளுநர்க்வ் மருந்துகள்இணைப்புகள் மற்றும் கையகப்படுத்துதல்